Autolus Therapeutics (AUTL) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

AUTL Stock Forecast

Autolus Therapeutics stock forecast is as follows: an average price target of $7.60 (represents a 231.88% upside from AUTL’s last price of $2.29) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.

AUTL Price Target

The average price target for Autolus Therapeutics (AUTL) is $7.60 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $7.60 to $7.60. This represents a potential 231.88% upside from AUTL's last price of $2.29.

AUTL Analyst Ratings

Buy

According to 4 Wall Street analysts, Autolus Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for AUTL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Autolus Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 18, 2024	Graig Suvannavejh	Goldman Sachs	$7.60	$3.03	150.99%	231.88%
May 20, 2024	Yanan Zhu	Wells Fargo	$8.00	$4.39	82.23%	249.34%
Apr 08, 2024	Asthika Goonewardene	Truist Financial	$11.00	$5.53	98.92%	380.35%
Mar 15, 2024	Asthika Goonewardene	Truist Financial	$10.00	$5.82	71.82%	336.68%

The latest Autolus Therapeutics stock forecast, released on Nov 18, 2024 by Graig Suvannavejh from Goldman Sachs, set a price target of $7.60, which represents a 150.99% increase from the stock price at the time of the forecast ($3.03), and a 231.88% increase from AUTL last price ($2.29).

Autolus Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	4
Avg Price Target	$7.60	$7.60	$9.15
Last Closing Price	$2.29	$2.29	$2.29
Upside/Downside	231.88%	231.88%	299.56%

In the current month, the average price target of Autolus Therapeutics stock is $7.60, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 231.88% increase as opposed to Autolus Therapeutics's last price of $2.29. This month's average price target is down 0.00% compared to last quarter, and down -16.94% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	Goldman Sachs		Buy	Upgrade
Jun 17, 2024	Needham	Buy	Buy	Hold
May 20, 2024	Wells Fargo	Overweight	Overweight	Hold
Mar 18, 2024	Needham	Buy	Buy	Hold
Mar 08, 2023	Piper Sandler	Buy	Buy	Hold
Dec 09, 2022	Needham	Buy	Buy	Hold

Autolus Therapeutics's last stock rating was published by Goldman Sachs on Nov 18, 2024. The company Upgrade its AUTL rating from "null" to "Buy".

Autolus Therapeutics Financial Forecast

Autolus Therapeutics Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$406.00K	-	$1.29M	$3.83M	$2.37M	-	-	$823.00K	-	$1.51M	$269.00K	-	$242.00K	$293.00K	$338.00K	$309.00K	$297.00K
Avg Forecast	$38.32M	$31.78M	$23.61M	$18.35M	$16.14M	$12.82M	$9.95M	$7.53M	$3.37M	$155.00K	$93.75K	$29.01M	$358.40K	$624.80K	$136.50K	$379.29K	$11.18M	$144.29K	$240.56K	$171.43K	$6.58M	$291.68K	$212.15K	$344.63K	$293.89K	$303.11K	$327.00K	$500.00K	$450.00K	$480.00K
High Forecast	$38.32M	$31.78M	$23.61M	$18.35M	$16.14M	$12.82M	$9.95M	$7.53M	$3.37M	$155.00K	$93.88K	$29.01M	$358.40K	$624.90K	$136.50K	$379.29K	$11.18M	$144.29K	$240.56K	$171.43K	$6.58M	$291.68K	$212.15K	$344.63K	$293.89K	$303.11K	$327.00K	$500.00K	$450.00K	$480.00K
Low Forecast	$38.32M	$31.78M	$23.61M	$18.35M	$16.14M	$12.82M	$9.95M	$7.53M	$3.37M	$155.00K	$93.63K	$29.01M	$358.40K	$624.70K	$136.50K	$379.29K	$11.18M	$144.29K	$240.56K	$171.43K	$6.58M	$291.68K	$212.15K	$344.63K	$293.89K	$303.11K	$327.00K	$500.00K	$450.00K	$480.00K
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	9	15	10	16	8	11	7	11
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	0.65%	-	3.41%	0.34%	16.42%	-	-	0.13%	-	7.10%	0.78%	-	0.80%	0.90%	0.68%	0.69%	0.62%

Autolus Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $358.40K, with a low forecast of $358.40K, and a high forecast of $358.40K. AUTL's average Quarter revenue forecast represents a -11.72% decrease compared to the company's last Quarter revenue of $406.00K (Sep 23).

Autolus Therapeutics EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	9	15	10	16	8	11	7	11
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$-40.89M	$-44.01M	$-42.47M	$-33.21M	$-26.45M	$-45.28M	$-45.80M	$-38.83M	$-45.50M	$-37.91M	$-35.48M	$-36.87M	$-45.67M	$-41.24M	$-38.28M	$-37.30M	$-37.69M	$-34.48M
Avg Forecast	$-38.32M	$-31.78M	$-23.61M	$-18.35M	$-16.14M	$-12.82M	$-9.95M	$-7.53M	$-3.37M	$-155.00K	$-93.75K	$-61.91M	$-358.40K	$-624.80K	$-136.50K	$-56.28M	$-25.62M	$-144.29K	$-240.56K	$-44.49M	$-6.58M	$-291.68K	$-212.15K	$-41.68M	$-293.89K	$-303.11K	$-327.00K	$-38.42M	$-450.00K	$-480.00K
High Forecast	$-38.32M	$-31.78M	$-23.61M	$-18.35M	$-16.14M	$-12.82M	$-9.95M	$-7.53M	$-3.37M	$-155.00K	$-93.63K	$-49.53M	$-358.40K	$-624.70K	$-136.50K	$-45.03M	$-20.50M	$-144.29K	$-240.56K	$-35.59M	$-6.58M	$-291.68K	$-212.15K	$-33.35M	$-293.89K	$-303.11K	$-327.00K	$-30.74M	$-450.00K	$-480.00K
Low Forecast	$-38.32M	$-31.78M	$-23.61M	$-18.35M	$-16.14M	$-12.82M	$-9.95M	$-7.53M	$-3.37M	$-155.00K	$-93.88K	$-74.29M	$-358.40K	$-624.90K	$-136.50K	$-67.54M	$-30.75M	$-144.29K	$-240.56K	$-53.39M	$-6.58M	$-291.68K	$-212.15K	$-50.02M	$-293.89K	$-303.11K	$-327.00K	$-46.10M	$-450.00K	$-480.00K
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	114.08%	70.44%	311.11%	0.59%	1.03%	313.84%	190.41%	0.87%	6.92%	129.96%	167.23%	0.88%	155.39%	136.06%	117.06%	0.97%	83.76%	71.83%

undefined analysts predict AUTL's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Autolus Therapeutics's previous annual EBITDA (undefined) of $NaN.

Autolus Therapeutics Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	9	15	10	16	8	11	7	11
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-77.17M	$-45.85M	$-45.55M	$-39.81M	$-26.95M	$-42.77M	$-42.06M	$-37.06M	$-41.67M	$-33.99M	$-33.17M	$-33.27M	$-42.86M	$-37.31M	$-32.05M	$-29.87M	$-40.94M	$-27.25M
Avg Forecast	$-39.02M	$-46.92M	$-58.41M	$-56.42M	$-54.43M	$-58.96M	$-61.13M	$-61.58M	$-54.65M	$-57.02M	$-51.75M	$-59.09M	$-67.29M	$-66.40M	$-59.46M	$-53.72M	$-23.40M	$-125.50M	$-111.73M	$-42.47M	$-102.57M	$-134.40M	$-132.63M	$-37.15M	$-203.66M	$-187.99M	$-188.58M	$-35.52M	$-196.41M	$-228.78M
High Forecast	$-39.02M	$-46.92M	$-58.41M	$-56.42M	$-54.43M	$-58.96M	$-61.13M	$-61.58M	$-13.01M	$-57.02M	$-51.75M	$-47.27M	$-59.52M	$-66.40M	$-59.46M	$-42.98M	$-18.72M	$-125.50M	$-111.73M	$-33.97M	$-102.57M	$-134.40M	$-132.63M	$-29.72M	$-203.66M	$-187.99M	$-188.58M	$-28.42M	$-196.41M	$-228.78M
Low Forecast	$-39.02M	$-46.92M	$-58.41M	$-56.42M	$-54.43M	$-58.96M	$-61.13M	$-61.58M	$-85.88M	$-57.02M	$-51.75M	$-70.91M	$-75.05M	$-66.40M	$-59.46M	$-64.46M	$-28.08M	$-125.50M	$-111.73M	$-50.96M	$-102.57M	$-134.40M	$-132.63M	$-44.58M	$-203.66M	$-187.99M	$-188.58M	$-42.63M	$-196.41M	$-228.78M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.15%	0.69%	0.77%	0.74%	1.15%	0.34%	0.38%	0.87%	0.41%	0.25%	0.25%	0.90%	0.21%	0.20%	0.17%	0.84%	0.21%	0.12%

Autolus Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AUTL's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Autolus Therapeutics SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	9	15	10	16	8	11	7	11
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$15.73M	$10.61M	$11.12M	$9.28M	$7.41M	$8.23M	$8.27M	$7.99M	$7.59M	$8.30M	$7.24M	$8.74M	$9.01M	$9.84M	$8.51M	$7.61M	$9.92M	$8.61M
Avg Forecast	$1.57B	$1.30B	$965.27M	$750.33M	$659.81M	$524.05M	$406.86M	$307.91M	$137.69M	$6.34M	$3.83M	$12.73M	$14.65M	$25.55M	$5.58M	$15.51M	$8.61M	$5.79M	$9.65M	$6.88M	$263.76M	$11.70M	$8.51M	$13.82M	$11.79M	$12.16M	$13.12M	$20.06M	$18.05M	$19.25M
High Forecast	$1.57B	$1.30B	$965.27M	$750.33M	$659.81M	$524.05M	$406.86M	$307.91M	$137.69M	$6.34M	$3.84M	$15.28M	$14.65M	$25.55M	$5.58M	$15.51M	$10.33M	$5.79M	$9.65M	$6.88M	$263.76M	$11.70M	$8.51M	$13.82M	$11.79M	$12.16M	$13.12M	$20.06M	$18.05M	$19.25M
Low Forecast	$1.57B	$1.30B	$965.27M	$750.33M	$659.81M	$524.05M	$406.86M	$307.91M	$137.69M	$6.34M	$3.83M	$10.19M	$14.65M	$25.54M	$5.58M	$15.51M	$6.88M	$5.79M	$9.65M	$6.88M	$263.76M	$11.70M	$8.51M	$13.82M	$11.79M	$12.16M	$13.12M	$20.06M	$18.05M	$19.25M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	0.42%	1.99%	0.60%	0.86%	1.42%	0.86%	1.16%	0.03%	0.71%	0.85%	0.63%	0.76%	0.81%	0.65%	0.38%	0.55%	0.45%

Autolus Therapeutics's average Quarter SG&A projection for Mar 24 is $12.73M, based on 1 Wall Street analysts, with a range of $10.19M to $15.28M. The forecast indicates a -19.03% fall compared to AUTL last annual SG&A of $15.73M (Dec 23).

Autolus Therapeutics EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	1	1	1	1	1	1	1	1	3	1	1	1	3	1	1	1	1	1	1	1	1	1	9	15	10	16	8	11	7	11
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.44	$-0.26	$-0.26	$-0.23	$-0.30	$-0.47	$-0.46	$-0.41	$-0.57	$-0.47	$-0.47	$-0.53	$-0.69	$-0.72	$-0.62	$-0.60	$-0.82	$-0.61
Avg Forecast	$-0.15	$-0.18	$-0.22	$-0.21	$-0.20	$-0.22	$-0.23	$-0.23	$-0.21	$-0.21	$-0.19	$-0.08	$-0.25	$-0.25	$-0.22	$-0.27	$-0.27	$-0.47	$-0.42	$-0.49	$-0.39	$-0.51	$-0.50	$-0.60	$-0.77	$-0.71	$-0.71	$-0.74	$-0.74	$-0.86
High Forecast	$-0.15	$-0.18	$-0.22	$-0.21	$-0.20	$-0.22	$-0.23	$-0.23	$-0.05	$-0.21	$-0.19	$-0.08	$-0.22	$-0.25	$-0.22	$-0.27	$-0.27	$-0.47	$-0.42	$-0.49	$-0.39	$-0.51	$-0.50	$-0.60	$-0.77	$-0.71	$-0.71	$-0.74	$-0.74	$-0.86
Low Forecast	$-0.15	$-0.18	$-0.22	$-0.21	$-0.20	$-0.22	$-0.23	$-0.23	$-0.32	$-0.21	$-0.19	$-0.08	$-0.28	$-0.25	$-0.22	$-0.27	$-0.27	$-0.47	$-0.42	$-0.49	$-0.39	$-0.51	$-0.50	$-0.60	$-0.77	$-0.71	$-0.71	$-0.74	$-0.74	$-0.86
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.74%	1.04%	1.16%	0.86%	1.12%	1.00%	1.10%	0.83%	1.48%	0.93%	0.94%	0.88%	0.90%	1.02%	0.87%	0.81%	1.11%	0.71%

According to undefined Wall Street analysts, Autolus Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AUTL previous annual EPS of $NaN (undefined).

Autolus Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
XFOR	X4 Pharmaceuticals	$0.74	$3.67	395.95%	Buy
ANEB	Anebulo Pharmaceuticals	$1.31	$6.00	358.02%	Buy
ABOS	Acumen Pharmaceuticals	$1.96	$7.00	257.14%	Buy
CELC	Celcuity	$12.55	$39.00	210.76%	Buy
AUTL	Autolus Therapeutics	$2.49	$7.60	205.22%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
LYRA	Lyra Therapeutics	$0.18	$0.50	177.78%	Hold
TERN	Terns Pharmaceuticals	$6.80	$18.67	174.56%	Buy
APLS	Apellis Pharmaceuticals	$34.53	$70.80	105.04%	Buy
AMLX	Amylyx Pharmaceuticals	$4.28	$8.25	92.76%	Buy
DAWN	Day One Biopharmaceuticals	$12.64	$24.00	89.87%	Buy
BOLT	Bolt Biotherapeutics	$0.54	$1.00	85.19%	Hold
RZLT	Rezolute	$4.44	$6.67	50.23%	Buy
IKNA	Ikena Oncology	$1.62	$1.33	-17.90%	Buy

AUTL Forecast FAQ

Is Autolus Therapeutics a good buy?

Yes, according to 4 Wall Street analysts, Autolus Therapeutics (AUTL) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of AUTL's total ratings.

What is AUTL's price target?

Autolus Therapeutics (AUTL) average price target is $7.6 with a range of $7.6 to $7.6, implying a 231.88% from its last price of $2.29. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Autolus Therapeutics stock go up soon?

According to Wall Street analysts' prediction for AUTL stock, the company can go up by 231.88% (from the last price of $2.29 to the average price target of $7.6), up by 231.88% based on the highest stock price target, and up by 231.88% based on the lowest stock price target.

Can Autolus Therapeutics stock reach $3?

AUTL's average twelve months analyst stock price target of $7.6 supports the claim that Autolus Therapeutics can reach $3 in the near future.

What is Autolus Therapeutics's current price target trend?

1 Wall Street analyst forecast a $7.6 price target for Autolus Therapeutics (AUTL) this month, up 231.88% from its last price of $2.29. Compared to the last 3 and 12 months, the average price target increased by 231.88% and increased by 299.56%, respectively.

What are Autolus Therapeutics's analysts' financial forecasts?

Autolus Therapeutics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $46.44M (high $46.44M, low $46.44M), average EBITDA is $-46.436M (high $-46.436M, low $-46.436M), average net income is $-236M (high $-236M, low $-236M), average SG&A $1.9B (high $1.9B, low $1.9B), and average EPS is $-0.887 (high $-0.887, low $-0.887). AUTL's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $112.06M (high $112.06M, low $112.06M), average EBITDA is $-112M (high $-112M, low $-112M), average net income is $-201M (high $-201M, low $-201M), average SG&A $4.58B (high $4.58B, low $4.58B), and average EPS is $-0.755 (high $-0.755, low $-0.755).

Did the AUTL's actual financial results beat the analysts' financial forecasts?

Based on Autolus Therapeutics's last annual report (Dec 2023), the company's revenue was $1.7M, beating the average analysts forecast of $1.5M by 13.28%. Apple's EBITDA was $-176M, beating the average prediction of $-57.402M by 205.79%. The company's net income was $-208M, missing the average estimation of $-247M by -15.59%. Apple's SG&A was $46.74M, missing the average forecast of $61.29M by -23.73%. Lastly, the company's EPS was $-1.2, beating the average prediction of $-0.993 by 20.82%. In terms of the last quarterly report (Sep 2023), Autolus Therapeutics's revenue was $406K, missing the average analysts' forecast of $624.8K by -35.02%. The company's EBITDA was $-44.014M, beating the average prediction of $-625K by 6944.49%. Autolus Therapeutics's net income was $-45.849M, missing the average estimation of $-66.399M by -30.95%. The company's SG&A was $10.61M, missing the average forecast of $25.55M by -58.46%. Lastly, the company's EPS was $-0.26, beating the average prediction of $-0.25 by 4.19%